BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy
BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: adult patients with active lupus nephritis who are receiving standard therapy.
BENLYSTA (belimumab) injection is a clear to opalescent, and colorless to pale yellow solution for subcutaneous use. Each single-dose prefilled syringe is designed to deliver 200 mg of belimumab in 1 mL of solution and is supplied as follows: 200 mg/mL single-dose prefilled glass syringe with 27-gauge, half-inch needle attached in a carton of 4 (NDC 49401-088-47).
Requires Refrigeration
Manufacturer # 49401008847
Brand Benlysta®
Manufacturer Glaxo Specialty
Country of Origin Unknown
Application Immunosuppressive Agent
Container Type Prefilled Syringe
Dosage Form Injection
Generic Drug Name Belimumab
Is_Active_Vendor Y
Is_DSCSA N
Is_Discontinued N
Is_Medical_Device Y
Lot_Tracking_Flag N
NDC Number 49401008847
On_Allocation N
Product Dating McKesson Acceptable Dating: we will ship >= 180 days
Quantity 4 per Box
Storage Requirements Requires Refrigeration
Strength 200 mg / mL
Supplier_ID 488095
Type Subcutaneous
UNSPSC Code 51202403
